Ariceum Therapeutics files for UK Clinical Trial Authorisation to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Ariceum Therapeutics Germany

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-files-for-uk-clinical-trial-authorisation-cta-to-test-its-first-in-class-iodine-123-labelled-parp-inhibitor-in-patients-with-recurrent-glioblastoma-302030247.html